Abstract：Objective: To observe the clinical effect of taking metoprolol tartrate combined with Guipi decoction by mouth in treating Cervical-cardiac Syndrome.Methods: Choose 78 cases of Cervical-cardiac Syndrome who seeing a doctor in our department from Jun 2016 to Jan 2018. And divided them into treatment group and control group according to random number table.39 cases in each group. The treatment group was treated by metoprolol tartrate combined with Guipi decoction, while the control group was treated by Guipi decoction only. 4 weeks was a course of treatment. Then appraise the change of bearing premature and SF-36 quality of life score. And record the complications on course of the treatment.Results: After treatment, the bearing premature are decreased and the SF-36 quality of life score is higher than pretherapy in the two groups. the treatment group and control group all have statistical significance( P<0.05),and the treatment group is better than the control group.Possess the statistical significance(P<0.05).Conclusion: The method of taking metoprolol tartrate combined with Guipi decoction by mouth can decrease the frequency of bearing premature and improve the quality of life in Cervical-cardiac Syndrome patients. And have no obvious adverse reaction.
[1] Nakae Y, Johkura K, Kudo Y, et al.Spinal cord infarction with cervical angina[J].Neurol Sci,2013,15:324(1~2):195~196. [2] 郭洋.以斜扳法为主治疗颈心综合征60例观察[J].中西医结合心脑血管病杂志,2014,12(2):252. [3] Van Genderen S,Plasqui G,Lacaille D,et al. Social role participation questionnaire for patients with ankylosing spondylitis:translation into Dutch,reliability and construct validity[J].RMD Open,2016,2(1) : e000177. [4] Morck B,Pullerits R,Geijer M,et al.Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study[J].Mediators In-flamm,2013,2013: 289845. [5] 孙浩,赵庆,杨春雷.葛根汤加减联合推拿治疗颈心综合征的疗效观察[J].中医药导报,2017,23(7):111~113. [6] Kato N,Naoko K, Kinugawa K,et al.Differertial impactsof achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation[J].Int Cardiol,2014,173(2):331~333. [7] Wafa hamdi,Azzouz D,Ghannouchi MM,et al. Health-related quality of life assessment on 100 tunisian patients with ankylosing spondylitis using the SF-36 survey[J].Oman Med,2012,27( 6) :455~460.
2018, Vol. 24 
冀公网安备13080202000677号